Pfizer raised its full-year outlook after it outperformed in the third quarter, as growing demand for its newer medicines helped the drugmaker offset declining sales of its Covid products
Pfizer on Tuesday reported third-quarter results that topped estimates and hiked its full-year outlook, as demand for its newly launched and acquired products grows.
Read more:
Pfizer yields 6%. That's more than most stablecoin farms, and it's Pfizer.
Split it and pick a side.
Want the dividend? Buy the dividend half. Six months of Pfizer's payout, one token, pocket change per share.
Want the rate? Buy the share half under par. Redeem at par in March. 6%+ fixed, in PFE, no lockup, sell whenever.
A 176-year-old drug company is our highest-paying series. For now. 💊